Integra Lifesciences Holdings (IART) Receivables (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Receivables data on file, last reported at $264.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 4.74% year-over-year to $264.4 million; the trailing twelve-month figure through Mar 2026 stood at $264.4 million (up 4.74% YoY), and the FY2025 full-year result was $278.8 million, up 2.38% from the prior year.
• Receivables eased to $264.4 million in Q1 2026, from $278.8 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $284.5 million in Q2 2025 to a low of $234.0 million in Q1 2022.
• A 5-year average of $258.0 million and a median of $258.7 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables advanced 13.65% in 2022 and dropped 5.08% in 2024, its largest moves.
• Tracing IART's Receivables over 5 years: stood at $263.5 million in 2022, then fell by 1.57% to $259.3 million in 2023, then climbed by 5.03% to $272.4 million in 2024, then gained by 2.38% to $278.8 million in 2025, then retreated by 5.18% to $264.4 million in 2026.
• Business Quant data shows IART's Receivables at $264.4 million in Q1 2026, $278.8 million in Q4 2025, and $262.2 million in Q3 2025.